PROCEPT BioRobotics Corporation

NASDAQ:PRCT

Medical - Devices

Healthcare
$25.18 +0.89%

+$0.19 today

Market cap
$1.45B
Beta
0.85
P/E (TTM)
-11.6
EPS (TTM)
-$1.81
52W Low $19.35High $62.17

Volume 2.05M

Average 1.46M

PRCT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

PROCEPT BioRobotics CorporationNASDAQ: PRCT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $21.47M rose 30.9% year over year, ahead of the +11.5% change in trailing-twelve-month research & development. Sequentially, it rose 12.6% from the prior quarter. Over 3 fiscal years it compounded at +35.0% a year.

Context

  • Research & development amounted to 23.1% of revenue in FY2025, down 4.6 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +30.9% holds above the trailing-twelve-month pace of +11.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$21.47M+12.6% QoQ
Last fiscal yearDec 2025
$71.28M+14.4% YoY
LTMMar 2026
$73.13M+11.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30.9%——
1 year+14.4%——
3-year CAGR+35.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
71.28M USD
Year-over-year change
+14.4%
4-year CAGR
+39.2%

Research & Development vs competitors

How PRCT compares with its peers on the latest reported figures

  • PRCT's LTM Mar 2026 research & development of $73.13M is the highest of the 5 companies compared; the peer median is $7.88M.
  • Its year-over-year change of +11.5% is the 3rd highest of 4, against a peer median of +14.4%.
  • Research & development amounts to 22.7% of revenue for PRCT, versus a peer median of 25.0%.
PRCT Competitors Peer median
Research & Development for PRCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026$73.13M +11.5%+35.0%22.7%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$15.04M +14.4%+8.5%37.0%
FOCLEDAP TMS S.A. American Depositary SharesLTM Mar 2026$9.65M —+18.8%13.0%
MBOTMicrobot Medical Inc.LTM Mar 2026$6.11M -11.4%-6.7%5814.3%
SSIISS Innovations International, Inc.LTM Mar 2026$3.67M +63.3%+253.7%7.6%
Peer median (excluding PRCT) $7.88M+14.4%+13.6%25.0%

Competitors are the stored peer set for PRCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.47M75.01M136.19M224.5M308.05M
Cost of Revenue18.61M37.93M65.14M87.4M111.83M
Gross Profit15.87M37.09M71.05M137.1M196.23M
Gross Margin46.0%49.4%52.2%61.1%63.7%
Research & Development18.99M28.98M48.45M62.3M71.28M
Selling, General & Admin51.04M88.83M131.77M171.42M228.81M
Operating Expenses70.03M117.81M180.22M233.71M300.09M
Depreciation & Amortization3.32M2.84M3.81M5.23M6.39M
EBITDA(50.72M)(79.13M)(98.1M)(82M)(85.41M)
EBITDA Margin-147.1%-105.5%-72.0%-36.5%-27.7%
Operating Income(54.16M)(80.72M)(109.17M)(96.61M)(103.86M)
Operating Margin-157.1%-107.6%-80.2%-43.0%-33.7%
Interest Income76K2.5M7.55M10.9M12.22M
Interest Expense5.81M5.18M4M4.18M3.59M
Other Income / Expenses(5.69M)(6.43M)3.27M5.2M8.48M
Income Before Tax(59.85M)(87.15M)(105.9M)(91.41M)(95.38M)
Pre-Tax Margin-173.6%-116.2%-77.8%-40.7%-31.0%
Income Tax Expense0000190K
Net Income(59.85M)(87.15M)(105.9M)(91.41M)(95.57M)
Net Margin-173.6%-116.2%-77.8%-40.7%-31.0%
EPS (Basic)(1.37)(1.96)(2.24)(1.75)(1.72)
EPS (Diluted)(1.37)(1.96)(2.24)(1.75)(1.72)
Weighted Avg Shares43.7M44.4M47.26M52.13M55.54M
Weighted Avg Shares (Diluted)43.7M44.4M47.26M52.13M55.54M

PROCEPT BioRobotics Corporation

NASDAQ:PRCT

Intrinsic Alpha fair value

Locked

Current Price

$25.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.